Sign in
Cost Effectiveness Analysis of The Use of Daclatasvir for the Treatment of Hepatitis C Virus (Hcv) Genotypes 3 in Cirrhotic Patients Within the Italian National Health Service
Conference proceeding   Peer reviewed

Cost Effectiveness Analysis of The Use of Daclatasvir for the Treatment of Hepatitis C Virus (Hcv) Genotypes 3 in Cirrhotic Patients Within the Italian National Health Service

Umberto Restelli, Marzia Bonfanti, Alfredo Alberti, Adriano Lazzarin, Carmela Nappi and Davide Croce
Value in health, Vol.18(7), pp.A587-A587
ISPOR 18th Annual European Congress (Milan, 07/11/2015 - 11/11/2015)
2015
Web of Science ID: WOS:000209861300457
PMID: 26533297
pdf
bitstream_89e5d9ea-e2b3-41bb-975f-27cd15f49b7753.47 kB
Ask the Library / Chiedi alla Biblioteca Restricted Access

Metrics

21 Record Views

Details